Financial analyst: Novo Nordisk's obesity treatment could triple market
Jefferies' analysts have consulted with an expert on obesity and diabetes treatments, and now, the investment banking company sees a real possibility that the market for obesity treatment will grow significantly.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk's novel weight loss drug Wegovy has the potential to at least double or triple the market, writes investment banking company Jefferies in a report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk expands collaboration with US app company
For subscribers
Coloplast sees potential in Russia
For subscribers
